We have developed the world’s first AMPA-Positron Emission Tomography (PET) technology that can image and quantify the distribution of AMPA-type receptors in the brain in vivo.
AMPA (receptor) + metry (measure) = Ampametry
It is our mission at Ampametry to spread this technology across the world and to pioneer novel neuropsychiatric research, diagnosis, and treatment.
With the world’s first AMPA-PET technology,
we are opening new doors for psychiatry and neuroscience.
AMPA receptors are one of the glutamate receptors in the brain and central nervous system that are involved in memory and learning. Studies have also shown that they are associated with many neuropsychiatric disorders such as epilepsy, schizophrenia, depression, and bipolar disorder. However, to date, measuring the distribution and density of AMPA receptors in vivo was not possible. Hence, research on the correlation between these diseases and the actual distribution of AMPA receptors in humans has been slow. Consequently, it has been difficult to develop therapeutic agents that target AMPA receptors.
PET is a type of imaging technique. Subjects are administered a radioisotope-labeled drug that emits positrons (positive electrons). This technology uses a device to measure the radiation emitted from a drug distributed in the body and create an image of the distribution of the drug. The characteristic of PET is that the image obtained changes depending on the radiopharmaceutical used. If FDG is used, it reflects glucose metabolism and is used for cancer detection.
We have developed a radiopharmaceutical K-2 that specifically binds to AMPA receptors and can help visualize AMPA receptor distribution in vivo. For the first time in the world, we successfully demonstrated the distribution of AMPA receptors in vivo. Currently, many clinical studies on neuropsychiatric disorders are being conducted using AMPA-PET.
Ampametry Co. Ltd. was established in September 2019. It is a startup company that aims for the worldwide utilization of the AMPA-PET technology, developed by the Department of Physiology, Yokohama City University School of Medicine. We support preclinical and clinical trials using AMPA-PET.
#P202 Sentanikagakukenkyuuto 3-9 Fukura Kanazawa-ku, Yokohama, Kanagawa 236-0004 Japan
The copyright of the content posted on this site belongs to Ampametry Co. Ltd. and it is prohibited to divert or copy it without permission.